Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2015-11-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02599090
Bioequivalence Study of Sorafenib Tablet and Nexavar
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2015-11-06
- Lead Sponsor
- Yabao Pharmaceutical Group
- Target Recruit Count
- 36
- Registration Number
- NCT02599337
- Locations
- 🇨🇦
Inventiv Health Clinique Inc., Québec, Quebec, Canada
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 743
- Registration Number
- NCT02576509
- Locations
- 🇮🇹
Local Institution - 0055, Milan, Italy
🇦🇹Local Institution - 0039, Graz, Austria
🇧🇪Local Institution - 0075, Bruxelles, Belgium
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 11
- Registration Number
- NCT02575339
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Penn State Cancer Institute, Hershey, Pennsylvania, United States
🇺🇸University of Illinois Cancer Center, Chicago, Illinois, United States
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
- Conditions
- Interventions
- First Posted Date
- 2015-09-29
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- SillaJen, Inc.
- Target Recruit Count
- 459
- Registration Number
- NCT02562755
- Locations
- 🇨🇳
Site No. 8306, Taichung, Taiwan
🇹🇭Site No. 8505, Bangkok, Thailand
🇹🇭Site No. 8503, Chiang Mai, Thailand
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-10-12
- Target Recruit Count
- 4
- Registration Number
- NCT02560012
- Locations
- 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States
Trial of TRC105 and Sorafenib in Patients With HCC
- Conditions
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Tracon Pharmaceuticals Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02560779
- Locations
- 🇺🇸
University Hospitals, Cleveland, Ohio, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸University of Alabama, Birmingham, Alabama, United States
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 500
- Registration Number
- NCT02559778
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
🇺🇸St. Lukes, Boise, Idaho, United States
🇺🇸Connecticut Children's Hospital, Hartford, Connecticut, United States
Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2016-03-15
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 90
- Registration Number
- NCT02537158
- Locations
- 🇨🇳
Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Bei jing, China
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT02530476
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.